Gitelman syndrome

Mendelian MONDO:0009904 Pathograph 11 inherited renal tubular disease renal salt-wasting tubulopathy renal tubular transport disease

Gitelman syndrome is an autosomal recessive inherited renal salt-wasting tubulopathy caused primarily by biallelic loss-of-function variants in SLC12A3, which encodes the thiazide-sensitive sodium-chloride cotransporter NCC in the distal convoluted tubule. Impaired NCC-mediated sodium chloride reabsorption causes chronic salt wasting, low-to-normal blood pressure, secondary renin-angiotensin-aldosterone system activation, renal potassium and hydrogen ion wasting, hypokalemic metabolic alkalosis, hypomagnesemia, and low urinary calcium excretion. Clinical expression is variable, often detected in adolescence or adulthood, and commonly includes muscle cramps or weakness, fatigue, salt craving, polydipsia/polyuria, growth or weight effects in childhood, prolonged QT interval risk, and reduced quality of life.

Ask OpenScientist

Ask a research question about Gitelman syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
5
Pathophys.
14
Phenotypes
11
Pathograph
2
Genes
4
Treatments
18
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0009904 Gitelman syndrome
skos:exactMatch Orphanet ORPHA:358
Orphanet ORPHA:358 lists MONDO:0009904 as an exact cross-reference for Gitelman syndrome.
📘

Definitions

1
Orphanet Gitelman syndrome definition
A rare syndrome characterized by hypokalemic metabolic alkalosis with significant hypomagnesemia and low urinary calcium excretion.
OTHER
Show evidence (1 reference)
ORPHA:358 SUPPORT Other
"hypokalemic metabolic alkalosis in combination with significant hypomagnesemia and low urinary calcium excretion"
Orphanet defines Gitelman syndrome by the core electrolyte pattern.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Gitelman syndrome is inherited in an autosomal recessive pattern.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance.
PMID:28003083 SUPPORT Other
"The disease is recessively inherited, caused by inactivating mutations in the SLC12A3 gene"
KDIGO consensus confirms recessive inheritance and the usual SLC12A3 cause.
⚙

Pathophysiology

5
NCC loss in distal convoluted tubule
SLC12A3 loss-of-function variants reduce NCC activity in distal convoluted tubule epithelial cells, decreasing thiazide-sensitive sodium chloride transport across the apical membrane.
distal convoluted tubule epithelial cell link
SLC12A3 link
renal sodium ion transport link ↓ DECREASED sodium ion transmembrane transport link ↓ DECREASED
distal convoluted tubule link
Downstream
Extracellular volume contraction
Altered distal calcium and magnesium handling
Show evidence (3 references)
PMID:28744758 SUPPORT Other
"mutations of the SLC12A3 gene that encodes the thiazide-sensitive sodium-chloride cotransporter in the early distal convoluted tubules"
Review connects SLC12A3 mutations to NCC in early distal convoluted tubules.
PMID:35173827 SUPPORT Other
"This gene encodes the thiazide-sensitive sodium-chloride cotransporter (NCC) which is exclusively expressed in the distal convoluted tubules (DCT)."
Review places NCC in distal convoluted tubules, supporting the cellular/anatomic location.
PMID:17329572 SUPPORT In Vitro
"Heterologous expression documented a novel class of NCC mutants with defective intrinsic transport activity."
Functional expression evidence supports impaired NCC transporter activity from disease-associated variants.
Extracellular volume contraction
Reduced distal sodium chloride reabsorption causes chronic renal salt wasting and extracellular volume contraction. Blood pressure remains low to normal because the tubular defect prevents effective sodium retention.
Downstream
Secondary RAAS activation
Show evidence (2 references)
PMID:28003083 SUPPORT Other
"Gitelman syndrome (GS) is a rare, salt-losing tubulopathy characterized by hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria."
KDIGO consensus defines Gitelman syndrome as a salt-losing tubulopathy.
PMID:20650971 SUPPORT Other
"hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis and hypereninemic hyperaldosteronism"
Review supports the biochemical consequence of salt wasting with RAAS activation.
Secondary RAAS activation
Extracellular volume contraction stimulates renin secretion and secondary aldosterone activation, which increases collecting-duct sodium reabsorption and drives potassium and hydrogen ion wasting.
renin secretion into blood stream link ↑ INCREASED
Downstream
Collecting-duct potassium and hydrogen wasting
Show evidence (2 references)
PMID:28744758 SUPPORT Other
"increased chloride excretion and renin/aldosterone levels"
Review supports increased renin and aldosterone as downstream hormonal responses.
PMID:20650971 SUPPORT Other
"hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis and hypereninemic hyperaldosteronism"
Review supports hyperreninemic hyperaldosteronism as part of the biochemical syndrome.
Collecting-duct potassium and hydrogen wasting
Salt wasting and aldosterone activation increase distal sodium delivery and collecting-duct sodium reabsorption, promoting potassium and hydrogen ion secretion. This produces hypokalemia and metabolic alkalosis and contributes to cramps, weakness, paralysis risk, and ventricular repolarization changes.
kidney collecting duct principal cell link
potassium ion homeostasis link ↓ DECREASED
Show evidence (2 references)
PMID:28744758 SUPPORT Other
"The syndrome is usually characterized by hypokalemic metabolic alkalosis in combination with hypomagnesemia and hypocalciuria."
Review supports hypokalemic metabolic alkalosis as the downstream biochemical pattern.
PMID:20848653 SUPPORT Model Organism
"Expression of epithelial Na(+) channel (Enac), Ca(2+) channels (Trpv5 and Trpv6), and K(+) channels (Romk1 and maxi-K) were significantly increased."
Knock-in mouse model shows compensatory distal/collecting-duct channel changes relevant to potassium wasting.
Altered distal calcium and magnesium handling
NCC loss in the distal convoluted tubule alters distal divalent cation handling, producing the diagnostic combination of hypomagnesemia and low urinary calcium excretion. The exact molecular coupling remains incompletely resolved, but distal convoluted tubule calcium-magnesium crosstalk and altered TRPV5/6 and related transport pathways are implicated.
magnesium ion homeostasis link ↓ DECREASED calcium ion homeostasis link ↓ DECREASED
Show evidence (2 references)
PMID:35173827 SUPPORT Other
"GS patients classically present with hypokalemic metabolic alkalosis with hypocalciuria and hypomagnesemia."
Review identifies hypocalciuria and hypomagnesemia as classic distal divalent-cation abnormalities.
PMID:35173827 SUPPORT Other
"the mechanisms by which hypomagnesemia and hypocalciuria develop in GS are poorly understood"
Review cautions that calcium-magnesium mechanism details remain incompletely resolved.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Gitelman syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Cardiovascular 1
Prolonged QT interval FREQUENT Prolonged QT interval (HP:0001657)
Show evidence (1 reference)
ORPHA:358 SUPPORT Other
"HP:0001657 | Prolonged QT interval | Frequent (79-30%)"
Orphanet records prolonged QT interval as frequent.
Genitourinary 2
Nocturia OCCASIONAL Nocturia (HP:0000017)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0000017 | Nocturia | Occasional (29-5%)"
Orphanet records nocturia as occasional.
PMID:30867665 SUPPORT Other
"It usually presents in late childhood or in teenage as nonspecific weakness, fatigability, polyuria, and polydipsia"
Systematic review supports polyuria/polydipsia as typical presenting symptoms.
Proteinuria OCCASIONAL Proteinuria (HP:0000093)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0000093 | Proteinuria | Occasional (29-5%)"
Orphanet records proteinuria as occasional.
PMID:41278357 SUPPORT Human Clinical
"a higher rate of albuminuria or proteinuria (28%)"
Large clinical survey supports albuminuria/proteinuria above the 10% review threshold.
Metabolism 1
Hypokalemia VERY_FREQUENT Hypokalemia (HP:0002900)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0002900 | Hypokalemia | Very frequent (99-80%)"
Orphanet records hypokalemia as very frequent.
PMID:28744758 SUPPORT Other
"hypokalemic metabolic alkalosis in combination with hypomagnesemia and hypocalciuria"
Review supports hypokalemia as part of the defining biochemical pattern.
Musculoskeletal 2
Muscle weakness FREQUENT Muscle weakness (HP:0001324)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0001324 | Muscle weakness | Frequent (79-30%)"
Orphanet records muscle weakness as frequent.
PMID:41278357 SUPPORT Human Clinical
"Physicians reported muscle cramps, salt craving, and muscle weakness as most common GS symptoms."
Large clinical survey supports muscle weakness as a common symptom.
Muscle spasm OCCASIONAL Muscle spasm (HP:0003394)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0003394 | Muscle spasm | Occasional (29-5%)"
Orphanet records muscle spasm as occasional.
PMID:41278357 SUPPORT Human Clinical
"Physicians reported muscle cramps, salt craving, and muscle weakness as most common GS symptoms."
Large clinical survey supports cramps as a common clinical symptom.
Nervous System 1
Salt craving OCCASIONAL Salt craving (HP:0030083)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0030083 | Salt craving | Occasional (29-5%)"
Orphanet records salt craving as occasional.
PMID:41278357 SUPPORT Human Clinical
"ranked salt craving and polydipsia-polyuria as the most severe symptoms"
Large survey supports salt craving as a major patient-reported symptom.
Constitutional 2
Abdominal pain FREQUENT Abdominal pain (HP:0002027)
Show evidence (1 reference)
ORPHA:358 SUPPORT Other
"HP:0002027 | Abdominal pain | Frequent (79-30%)"
Orphanet records abdominal pain as frequent.
Fatigue Fatigue (HP:0012378)
Show evidence (1 reference)
PMID:41278357 SUPPORT Human Clinical
"Patients with GS scored worse than the general population in fatigue, physical, and cognitive function"
Large clinical survey supports fatigue as a patient-reported symptom burden.
Growth 1
Failure to thrive FREQUENT Failure to thrive (HP:0001508)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0001508 | Failure to thrive | Frequent (79-30%)"
Orphanet records failure to thrive as frequent.
PMID:41278357 SUPPORT Human Clinical
"Children with GS were shorter and lighter than the general population, with lower bodyweight persisting into adulthood."
Large survey supports impaired growth/weight in pediatric Gitelman syndrome.
Other 4
Hypomagnesemia FREQUENT Hypomagnesemia (HP:0002917)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0002917 | Hypomagnesemia | Frequent (79-30%)"
Orphanet records hypomagnesemia as frequent.
PMID:41278357 SUPPORT Human Clinical
"Symptom burden was higher in adult females and patients with lower blood magnesium."
Large clinical survey links lower magnesium with higher symptom burden.
Metabolic alkalosis OCCASIONAL Metabolic alkalosis (HP:0200114)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0200114 | Metabolic alkalosis | Occasional (29-5%)"
Orphanet records metabolic alkalosis in the HPO table.
PMID:28003083 SUPPORT Other
"hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria"
KDIGO consensus supports metabolic alkalosis as a defining feature.
Low-to-normal blood pressure FREQUENT Low-to-normal blood pressure (HP:0002632)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0002632 | Low-to-normal blood pressure | Frequent (79-30%)"
Orphanet records low-to-normal blood pressure as frequent.
PMID:41278357 SUPPORT Human Clinical
"Compared with the general population, adult patients with GS had lower rates of chronic kidney disease (CKD) and hypertension"
Large survey supports lower hypertension rates consistent with a salt-wasting phenotype.
Chondrocalcinosis VERY_RARE Chondrocalcinosis (HP:0000934)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"HP:0000934 | Chondrocalcinosis | Very rare (<4-1%)"
Orphanet records chondrocalcinosis as very rare.
PMID:41278357 SUPPORT Human Clinical
"Adult patients with GS had a high prevalence of chondrocalcinosis (15%)"
Large clinical survey supports chondrocalcinosis in adults with Gitelman syndrome.
🧬

Genetic Associations

2
SLC12A3 (Causal loss-of-function variant)
Show evidence (3 references)
ORPHA:358 SUPPORT Other
"SLC12A3 | solute carrier family 12 member 3 | hgnc:10912 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet lists loss-of-function SLC12A3 variants as disease-causing.
PMID:8528245 SUPPORT Human Clinical
"identify a wide variety of non-conservative mutations, consistent with loss of function alleles, in affected subjects"
Original mapping study identifies SLC12A3 loss-of-function alleles in affected individuals.
PMID:41278357 SUPPORT Human Clinical
"Data from 587 patients (25% pediatric) across 13 countries showed 93% were genotyped, with 94% having variants in SLC12A3."
Large 2025 clinical survey confirms SLC12A3 predominance among genotyped patients.
CLCNKB (Gitelman-like loss-of-function variant)
Show evidence (1 reference)
ORPHA:358 SUPPORT Other
"CLCNKB | chloride voltage-gated channel Kb | hgnc:2027 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet lists CLCNKB loss-of-function variants in the Gitelman syndrome structured record.
💊

Treatments

4
Liberal salt intake
Action: dietary intervention MAXO:0000088
Agent: sodium chloride ↗
Liberal salt intake helps compensate for chronic renal sodium chloride wasting and is recommended with oral magnesium and potassium supplements.
Show evidence (1 reference)
PMID:28003083 SUPPORT Other
"GS is usually managed by a liberal salt intake together with oral magnesium and potassium supplements."
KDIGO consensus supports liberal salt intake as part of usual management.
Potassium supplementation
Action: Pharmacotherapy NCIT:C15986
Agent: potassium chloride ↗
Oral potassium chloride supplementation is used to counter chronic potassium wasting and reduce hypokalemia-related symptoms and arrhythmia risk.
Target Phenotypes: Hypokalemia ↗
Show evidence (2 references)
PMID:28003083 SUPPORT Other
"oral magnesium and potassium supplements"
KDIGO consensus supports potassium supplementation.
PMID:41278357 SUPPORT Human Clinical
"Treatment mainly consisted of potassium (94%) and magnesium (50%) supplementation."
Large survey documents potassium supplementation in current clinical practice.
Magnesium supplementation
Action: Pharmacotherapy NCIT:C15986
Agent: magnesium ion ↗
Oral magnesium supplementation targets hypomagnesemia and may also help stabilize potassium by improving magnesium-dependent potassium handling.
Target Phenotypes: Hypomagnesemia ↗
Show evidence (2 references)
PMID:28003083 SUPPORT Other
"oral magnesium and potassium supplements"
KDIGO consensus supports magnesium supplementation.
PMID:41278357 SUPPORT Human Clinical
"Treatment mainly consisted of potassium (94%) and magnesium (50%) supplementation."
Large survey documents magnesium supplementation in current clinical practice.
Potassium-sparing medication
Action: Pharmacotherapy NCIT:C15986
Agent: amiloride ↗ spironolactone ↗ eplerenone ↗
Potassium-sparing agents such as amiloride, spironolactone, or eplerenone can be used when supplementation alone does not adequately improve serum potassium or symptoms.
Target Phenotypes: Hypokalemia ↗
Show evidence (1 reference)
PMID:41278357 SUPPORT Human Clinical
"Potassium-sparing medication (used in 33%) slightly increased blood potassium levels (3.2 vs. 3.1 mmol/l)."
Large survey supports use and modest biochemical effect of potassium-sparing medication.
🔬

Biochemical Markers

5
Serum potassium (DECREASED)
Show evidence (1 reference)
PMID:28744758 SUPPORT Other
"The syndrome is usually characterized by hypokalemic metabolic alkalosis in combination with hypomagnesemia and hypocalciuria."
Review supports decreased serum potassium.
Serum magnesium (DECREASED)
Show evidence (1 reference)
PMID:35173827 SUPPORT Other
"GS patients classically present with hypokalemic metabolic alkalosis with hypocalciuria and hypomagnesemia."
Review supports decreased serum magnesium.
Urinary calcium excretion (DECREASED)
Show evidence (2 references)
ORPHA:358 SUPPORT Other
"low urinary calcium excretion"
Orphanet definition includes low urinary calcium excretion.
PMID:28003083 SUPPORT Other
"hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria"
KDIGO consensus supports hypocalciuria as a core biochemical feature.
Renin-angiotensin-aldosterone activity (INCREASED)
Show evidence (1 reference)
PMID:28744758 SUPPORT Other
"increased chloride excretion and renin/aldosterone levels"
Review supports increased renin/aldosterone levels.
Serum phosphate (DECREASED)
Show evidence (1 reference)
PMID:41278357 SUPPORT Human Clinical
"Patients with GS had the expected electrolyte disorders as well as significantly lower blood phosphate levels."
Large clinical survey supports decreased serum phosphate as an additional biochemical abnormality.
{ }

Source YAML

click to show 
name: Gitelman syndrome
category: Mendelian
creation_date: '2026-05-03T20:36:52Z'
updated_date: '2026-05-09T03:15:56Z'
synonyms:
- Gitelman's syndrome
- Familial hypokalemia-hypomagnesemia
- Primary renal tubular hypokalemic hypomagnesemia with hypocalciuria
description: >
  Gitelman syndrome is an autosomal recessive inherited renal salt-wasting
  tubulopathy caused primarily by biallelic loss-of-function variants in
  SLC12A3, which encodes the thiazide-sensitive sodium-chloride cotransporter
  NCC in the distal convoluted tubule. Impaired NCC-mediated sodium chloride
  reabsorption causes chronic salt wasting, low-to-normal blood pressure,
  secondary renin-angiotensin-aldosterone system activation, renal potassium and
  hydrogen ion wasting, hypokalemic metabolic alkalosis, hypomagnesemia, and low
  urinary calcium excretion. Clinical expression is variable, often detected in
  adolescence or adulthood, and commonly includes muscle cramps or weakness,
  fatigue, salt craving, polydipsia/polyuria, growth or weight effects in
  childhood, prolonged QT interval risk, and reduced quality of life.
disease_term:
  preferred_term: Gitelman syndrome
  term:
    id: MONDO:0009904
    label: Gitelman syndrome
parents:
- inherited renal tubular disease
- renal salt-wasting tubulopathy
- renal tubular transport disease
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009904
      label: Gitelman syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:358
    mapping_justification: >
      Orphanet ORPHA:358 lists MONDO:0009904 as an exact cross-reference for
      Gitelman syndrome.
external_assertions:
- name: Orphanet Gitelman syndrome record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:358
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=358
  description: >
    Orphanet's ORPHA:358 structured record provides the exact MONDO and OMIM
    mappings, autosomal recessive inheritance, definition, disease-gene
    assertions for SLC12A3 and CLCNKB, prevalence, and HPO annotations used in
    this curation.
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0009904 | Exact"
    explanation: Orphanet maps ORPHA:358 exactly to the MONDO identifier used here.
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:263800 | Exact"
    explanation: Orphanet lists OMIM:263800 as an exact external cross-reference.
definitions:
- name: Orphanet Gitelman syndrome definition
  definition_type: OTHER
  description: >
    A rare syndrome characterized by hypokalemic metabolic alkalosis with
    significant hypomagnesemia and low urinary calcium excretion.
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypokalemic metabolic alkalosis in combination with significant hypomagnesemia and low urinary calcium excretion"
    explanation: Orphanet defines Gitelman syndrome by the core electrolyte pattern.
inheritance:
- name: Autosomal recessive inheritance
  description: Gitelman syndrome is inherited in an autosomal recessive pattern.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance.
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The disease is recessively inherited, caused by inactivating mutations in the SLC12A3 gene"
    explanation: KDIGO consensus confirms recessive inheritance and the usual SLC12A3 cause.
prevalence:
- population: Europe
  notes: >
    Orphanet records a European point-prevalence band of 1-9 per 100,000.
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Europe | Point prevalence | ORPHANET"
    explanation: Orphanet provides the regional point-prevalence band.
progression:
- phase: Recognition and chronic course
  age_range: Childhood to adulthood
  notes: >
    Gitelman syndrome is often recognized in adolescence or adulthood after
    incidental electrolyte testing or nonspecific symptoms, but childhood
    presentation with impaired growth or more severe manifestations also occurs.
  evidence:
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GS is usually detected during adolescence or adulthood, either fortuitously or in association with mild or nonspecific symptoms or both."
    explanation: KDIGO consensus supports the usual timing and mode of recognition.
  - reference: PMID:17329572
    reference_title: "Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A subgroup of patients presented with early onset, growth retardation, and/or detrimental manifestations, confirming the potential severity of GS."
    explanation: Patient cohort plus functional study supports severe and early-onset presentations in a subset.
- phase: Long-term symptom burden
  age_range: Childhood to adulthood
  notes: >
    Long-term burden is driven by electrolyte derangements, cramps, weakness,
    salt craving, polydipsia/polyuria, fatigue, cognitive and physical function
    effects, and adult complications such as chondrocalcinosis or
    albuminuria/proteinuria in some cohorts.
  evidence:
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with GS scored worse than the general population in fatigue, physical, and cognitive function; and ranked salt craving and polydipsia-polyuria as the most severe symptoms."
    explanation: The 2025 multinational survey documents patient-reported long-term burden.
genetic:
- name: SLC12A3
  association: Causal loss-of-function variant
  gene_term:
    preferred_term: SLC12A3
    term:
      id: hgnc:10912
      label: SLC12A3
  notes: >
    Biallelic inactivating variants in SLC12A3 impair NCC-mediated sodium
    chloride transport in the distal convoluted tubule and are the primary
    molecular cause of Gitelman syndrome.
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLC12A3 | solute carrier family 12 member 3 | hgnc:10912 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet lists loss-of-function SLC12A3 variants as disease-causing.
  - reference: PMID:8528245
    reference_title: "Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identify a wide variety of non-conservative mutations, consistent with loss of function alleles, in affected subjects"
    explanation: Original mapping study identifies SLC12A3 loss-of-function alleles in affected individuals.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Data from 587 patients (25% pediatric) across 13 countries showed 93% were genotyped, with 94% having variants in SLC12A3."
    explanation: Large 2025 clinical survey confirms SLC12A3 predominance among genotyped patients.
- name: CLCNKB
  association: Gitelman-like loss-of-function variant
  gene_term:
    preferred_term: CLCNKB
    term:
      id: hgnc:2027
      label: CLCNKB
  notes: >
    Orphanet also lists loss-of-function CLCNKB variants for this Orpha record.
    CLCNKB is more classically modeled in Bartter syndrome type 3, but some
    individuals have a Gitelman-like biochemical presentation. This entry keeps
    the central mechanism on SLC12A3/NCC and records CLCNKB as an overlapping
    Gitelman-like genotype.
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLCNKB | chloride voltage-gated channel Kb | hgnc:2027 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet lists CLCNKB loss-of-function variants in the Gitelman syndrome structured record.
pathophysiology:
- name: NCC loss in distal convoluted tubule
  description: >
    SLC12A3 loss-of-function variants reduce NCC activity in distal convoluted
    tubule epithelial cells, decreasing thiazide-sensitive sodium chloride
    transport across the apical membrane.
  genes:
  - preferred_term: SLC12A3
    term:
      id: hgnc:10912
      label: SLC12A3
  cell_types:
  - preferred_term: distal convoluted tubule epithelial cell
    term:
      id: CL:1000494
      label: nephron tubule epithelial cell
  locations:
  - preferred_term: distal convoluted tubule
    term:
      id: UBERON:0001292
      label: distal convoluted tubule
  biological_processes:
  - preferred_term: renal sodium ion transport
    modifier: DECREASED
    term:
      id: GO:0003096
      label: renal sodium ion transport
  - preferred_term: sodium ion transmembrane transport
    modifier: DECREASED
    term:
      id: GO:0035725
      label: sodium ion transmembrane transport
  evidence:
  - reference: PMID:28744758
    reference_title: "Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "mutations of the SLC12A3 gene that encodes the thiazide-sensitive sodium-chloride cotransporter in the early distal convoluted tubules"
    explanation: Review connects SLC12A3 mutations to NCC in early distal convoluted tubules.
  - reference: PMID:35173827
    reference_title: Renal calcium and magnesium handling in Gitelman syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This gene encodes the thiazide-sensitive sodium-chloride cotransporter (NCC) which is exclusively expressed in the distal convoluted tubules (DCT)."
    explanation: Review places NCC in distal convoluted tubules, supporting the cellular/anatomic location.
  - reference: PMID:17329572
    reference_title: "Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Heterologous expression documented a novel class of NCC mutants with defective intrinsic transport activity."
    explanation: Functional expression evidence supports impaired NCC transporter activity from disease-associated variants.
  downstream:
  - target: Extracellular volume contraction
    causal_link_type: DIRECT
  - target: Altered distal calcium and magnesium handling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Extracellular volume contraction
  description: >
    Reduced distal sodium chloride reabsorption causes chronic renal salt
    wasting and extracellular volume contraction. Blood pressure remains low to
    normal because the tubular defect prevents effective sodium retention.
  evidence:
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Gitelman syndrome (GS) is a rare, salt-losing tubulopathy characterized by hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria."
    explanation: KDIGO consensus defines Gitelman syndrome as a salt-losing tubulopathy.
  - reference: PMID:20650971
    reference_title: "Gitelman syndrome: pathophysiological and clinical aspects."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis and hypereninemic hyperaldosteronism"
    explanation: Review supports the biochemical consequence of salt wasting with RAAS activation.
  downstream:
  - target: Secondary RAAS activation
    causal_link_type: DIRECT
- name: Secondary RAAS activation
  description: >
    Extracellular volume contraction stimulates renin secretion and secondary
    aldosterone activation, which increases collecting-duct sodium reabsorption
    and drives potassium and hydrogen ion wasting.
  biological_processes:
  - preferred_term: renin secretion into blood stream
    modifier: INCREASED
    term:
      id: GO:0002001
      label: renin secretion into blood stream
  evidence:
  - reference: PMID:28744758
    reference_title: "Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "increased chloride excretion and renin/aldosterone levels"
    explanation: Review supports increased renin and aldosterone as downstream hormonal responses.
  - reference: PMID:20650971
    reference_title: "Gitelman syndrome: pathophysiological and clinical aspects."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis and hypereninemic hyperaldosteronism"
    explanation: Review supports hyperreninemic hyperaldosteronism as part of the biochemical syndrome.
  downstream:
  - target: Collecting-duct potassium and hydrogen wasting
    causal_link_type: DIRECT
- name: Collecting-duct potassium and hydrogen wasting
  description: >
    Salt wasting and aldosterone activation increase distal sodium delivery and
    collecting-duct sodium reabsorption, promoting potassium and hydrogen ion
    secretion. This produces hypokalemia and metabolic alkalosis and contributes
    to cramps, weakness, paralysis risk, and ventricular repolarization changes.
  cell_types:
  - preferred_term: kidney collecting duct principal cell
    term:
      id: CL:1001431
      label: kidney collecting duct principal cell
  biological_processes:
  - preferred_term: potassium ion homeostasis
    modifier: DECREASED
    term:
      id: GO:0055075
      label: potassium ion homeostasis
  evidence:
  - reference: PMID:28744758
    reference_title: "Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The syndrome is usually characterized by hypokalemic metabolic alkalosis in combination with hypomagnesemia and hypocalciuria."
    explanation: Review supports hypokalemic metabolic alkalosis as the downstream biochemical pattern.
  - reference: PMID:20848653
    reference_title: Generation and analysis of the thiazide-sensitive Na+ -Cl- cotransporter (Ncc/Slc12a3) Ser707X knockin mouse as a model of Gitelman syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Expression of epithelial Na(+) channel (Enac), Ca(2+) channels (Trpv5 and Trpv6), and K(+) channels (Romk1 and maxi-K) were significantly increased."
    explanation: Knock-in mouse model shows compensatory distal/collecting-duct channel changes relevant to potassium wasting.
- name: Altered distal calcium and magnesium handling
  description: >
    NCC loss in the distal convoluted tubule alters distal divalent cation
    handling, producing the diagnostic combination of hypomagnesemia and low
    urinary calcium excretion. The exact molecular coupling remains incompletely
    resolved, but distal convoluted tubule calcium-magnesium crosstalk and
    altered TRPV5/6 and related transport pathways are implicated.
  biological_processes:
  - preferred_term: magnesium ion homeostasis
    modifier: DECREASED
    term:
      id: GO:0010960
      label: magnesium ion homeostasis
  - preferred_term: calcium ion homeostasis
    modifier: DECREASED
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  evidence:
  - reference: PMID:35173827
    reference_title: Renal calcium and magnesium handling in Gitelman syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GS patients classically present with hypokalemic metabolic alkalosis with hypocalciuria and hypomagnesemia."
    explanation: Review identifies hypocalciuria and hypomagnesemia as classic distal divalent-cation abnormalities.
  - reference: PMID:35173827
    reference_title: Renal calcium and magnesium handling in Gitelman syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the mechanisms by which hypomagnesemia and hypocalciuria develop in GS are poorly understood"
    explanation: Review cautions that calcium-magnesium mechanism details remain incompletely resolved.
phenotypes:
- category: Biochemical
  name: Hypokalemia
  description: >
    Low circulating potassium is the dominant electrolyte abnormality and a
    driver of weakness, cramps, paralysis risk, and electrocardiographic
    repolarization abnormalities.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypokalemia
    term:
      id: HP:0002900
      label: Hypokalemia
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002900 | Hypokalemia | Very frequent (99-80%)"
    explanation: Orphanet records hypokalemia as very frequent.
  - reference: PMID:28744758
    reference_title: "Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypokalemic metabolic alkalosis in combination with hypomagnesemia and hypocalciuria"
    explanation: Review supports hypokalemia as part of the defining biochemical pattern.
- category: Biochemical
  name: Hypomagnesemia
  description: >
    Low circulating magnesium is common and contributes to neuromuscular and
    cardiac manifestations; lower blood magnesium was associated with greater
    symptom burden in a 2025 survey.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypomagnesemia
    term:
      id: HP:0002917
      label: Hypomagnesemia
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002917 | Hypomagnesemia | Frequent (79-30%)"
    explanation: Orphanet records hypomagnesemia as frequent.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptom burden was higher in adult females and patients with lower blood magnesium."
    explanation: Large clinical survey links lower magnesium with higher symptom burden.
- category: Biochemical
  name: Metabolic alkalosis
  description: >
    Metabolic alkalosis follows from increased distal hydrogen ion secretion in
    the setting of volume contraction, aldosterone activation, and potassium
    wasting.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Metabolic alkalosis
    term:
      id: HP:0200114
      label: Metabolic alkalosis
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0200114 | Metabolic alkalosis | Occasional (29-5%)"
    explanation: Orphanet records metabolic alkalosis in the HPO table.
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria"
    explanation: KDIGO consensus supports metabolic alkalosis as a defining feature.
- category: Clinical
  name: Low-to-normal blood pressure
  description: >
    Chronic salt wasting typically produces normal or low blood pressure despite
    renin and aldosterone activation.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Low-to-normal blood pressure
    term:
      id: HP:0002632
      label: Low-to-normal blood pressure
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002632 | Low-to-normal blood pressure | Frequent (79-30%)"
    explanation: Orphanet records low-to-normal blood pressure as frequent.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared with the general population, adult patients with GS had lower rates of chronic kidney disease (CKD) and hypertension"
    explanation: Large survey supports lower hypertension rates consistent with a salt-wasting phenotype.
- category: Clinical
  name: Muscle weakness
  description: >
    Muscle weakness reflects chronic or episodic potassium and magnesium
    depletion and is among the most commonly reported symptoms.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001324 | Muscle weakness | Frequent (79-30%)"
    explanation: Orphanet records muscle weakness as frequent.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physicians reported muscle cramps, salt craving, and muscle weakness as most common GS symptoms."
    explanation: Large clinical survey supports muscle weakness as a common symptom.
- category: Clinical
  name: Failure to thrive
  description: >
    Pediatric patients can have growth and weight effects, particularly in more
    severe or early-onset disease.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001508 | Failure to thrive | Frequent (79-30%)"
    explanation: Orphanet records failure to thrive as frequent.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Children with GS were shorter and lighter than the general population, with lower bodyweight persisting into adulthood."
    explanation: Large survey supports impaired growth/weight in pediatric Gitelman syndrome.
- category: Clinical
  name: Prolonged QT interval
  description: >
    Potassium and magnesium depletion can prolong ventricular repolarization and
    increase arrhythmia risk.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Prolonged QT interval
    term:
      id: HP:0001657
      label: Prolonged QT interval
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001657 | Prolonged QT interval | Frequent (79-30%)"
    explanation: Orphanet records prolonged QT interval as frequent.
- category: Clinical
  name: Abdominal pain
  description: >
    Abdominal pain is recorded among frequent Orphanet HPO features and may
    occur with electrolyte disturbance or supplement intolerance.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002027 | Abdominal pain | Frequent (79-30%)"
    explanation: Orphanet records abdominal pain as frequent.
- category: Clinical
  name: Muscle spasm
  description: >
    Cramps and spasms are common neuromuscular consequences of chronic
    potassium and magnesium depletion.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Muscle spasm
    term:
      id: HP:0003394
      label: Muscle spasm
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003394 | Muscle spasm | Occasional (29-5%)"
    explanation: Orphanet records muscle spasm as occasional.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physicians reported muscle cramps, salt craving, and muscle weakness as most common GS symptoms."
    explanation: Large clinical survey supports cramps as a common clinical symptom.
- category: Clinical
  name: Salt craving
  description: >
    Salt craving reflects chronic renal salt wasting and is among the symptoms
    patients rated as most severe in the 2025 survey.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Salt craving
    term:
      id: HP:0030083
      label: Salt craving
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0030083 | Salt craving | Occasional (29-5%)"
    explanation: Orphanet records salt craving as occasional.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ranked salt craving and polydipsia-polyuria as the most severe symptoms"
    explanation: Large survey supports salt craving as a major patient-reported symptom.
- category: Clinical
  name: Nocturia
  description: >
    Nocturia and polyuria/polydipsia can occur as part of chronic salt-wasting
    tubulopathy.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Nocturia
    term:
      id: HP:0000017
      label: Nocturia
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000017 | Nocturia | Occasional (29-5%)"
    explanation: Orphanet records nocturia as occasional.
  - reference: PMID:30867665
    reference_title: "Gitelman Syndrome: A Rare Cause of Seizure Disorder and a Systematic Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It usually presents in late childhood or in teenage as nonspecific weakness, fatigability, polyuria, and polydipsia"
    explanation: Systematic review supports polyuria/polydipsia as typical presenting symptoms.
- category: Clinical
  name: Chondrocalcinosis
  description: >
    Adult patients can develop chondrocalcinosis, likely related to chronic
    magnesium depletion.
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Chondrocalcinosis
    term:
      id: HP:0000934
      label: Chondrocalcinosis
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000934 | Chondrocalcinosis | Very rare (<4-1%)"
    explanation: Orphanet records chondrocalcinosis as very rare.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult patients with GS had a high prevalence of chondrocalcinosis (15%)"
    explanation: Large clinical survey supports chondrocalcinosis in adults with Gitelman syndrome.
- category: Clinical
  name: Proteinuria
  description: >
    Albuminuria or proteinuria was reported in 28% of adult patients in a
    multinational Gitelman syndrome survey and is also listed in Orphanet.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000093 | Proteinuria | Occasional (29-5%)"
    explanation: Orphanet records proteinuria as occasional.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a higher rate of albuminuria or proteinuria (28%)"
    explanation: Large clinical survey supports albuminuria/proteinuria above the 10% review threshold.
- category: Clinical
  name: Fatigue
  description: >
    Fatigue is a prominent patient-reported burden in Gitelman syndrome,
    occurring with physical and cognitive function impairment in the 2025 survey.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with GS scored worse than the general population in fatigue, physical, and cognitive function"
    explanation: Large clinical survey supports fatigue as a patient-reported symptom burden.
biochemical:
- name: Serum potassium
  presence: DECREASED
  notes: Low serum potassium due to renal potassium wasting downstream of salt wasting and aldosterone activation.
  evidence:
  - reference: PMID:28744758
    reference_title: "Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The syndrome is usually characterized by hypokalemic metabolic alkalosis in combination with hypomagnesemia and hypocalciuria."
    explanation: Review supports decreased serum potassium.
- name: Serum magnesium
  presence: DECREASED
  notes: Low serum magnesium due to altered distal convoluted tubule magnesium handling.
  evidence:
  - reference: PMID:35173827
    reference_title: Renal calcium and magnesium handling in Gitelman syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GS patients classically present with hypokalemic metabolic alkalosis with hypocalciuria and hypomagnesemia."
    explanation: Review supports decreased serum magnesium.
- name: Urinary calcium excretion
  presence: DECREASED
  notes: Low urinary calcium excretion is a key biochemical discriminator from many Bartter phenotypes.
  evidence:
  - reference: ORPHA:358
    reference_title: "Gitelman syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "low urinary calcium excretion"
    explanation: Orphanet definition includes low urinary calcium excretion.
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria"
    explanation: KDIGO consensus supports hypocalciuria as a core biochemical feature.
- name: Renin-angiotensin-aldosterone activity
  presence: INCREASED
  notes: Secondary RAAS activation follows renal salt wasting.
  evidence:
  - reference: PMID:28744758
    reference_title: "Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "increased chloride excretion and renin/aldosterone levels"
    explanation: Review supports increased renin/aldosterone levels.
- name: Serum phosphate
  presence: DECREASED
  notes: Lower blood phosphate was observed in the 2025 multinational survey of Gitelman syndrome patients.
  evidence:
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with GS had the expected electrolyte disorders as well as significantly lower blood phosphate levels."
    explanation: Large clinical survey supports decreased serum phosphate as an additional biochemical abnormality.
treatments:
- name: Liberal salt intake
  description: >
    Liberal salt intake helps compensate for chronic renal sodium chloride
    wasting and is recommended with oral magnesium and potassium supplements.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
    therapeutic_agent:
    - preferred_term: sodium chloride
      term:
        id: CHEBI:26710
        label: sodium chloride
  evidence:
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GS is usually managed by a liberal salt intake together with oral magnesium and potassium supplements."
    explanation: KDIGO consensus supports liberal salt intake as part of usual management.
- name: Potassium supplementation
  description: >
    Oral potassium chloride supplementation is used to counter chronic potassium
    wasting and reduce hypokalemia-related symptoms and arrhythmia risk.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: potassium chloride
      term:
        id: CHEBI:32588
        label: potassium chloride
  target_phenotypes:
  - preferred_term: Hypokalemia
    term:
      id: HP:0002900
      label: Hypokalemia
  evidence:
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "oral magnesium and potassium supplements"
    explanation: KDIGO consensus supports potassium supplementation.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment mainly consisted of potassium (94%) and magnesium (50%) supplementation."
    explanation: Large survey documents potassium supplementation in current clinical practice.
- name: Magnesium supplementation
  description: >
    Oral magnesium supplementation targets hypomagnesemia and may also help
    stabilize potassium by improving magnesium-dependent potassium handling.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: magnesium ion
      term:
        id: CHEBI:39128
        label: magnesium ion
  target_phenotypes:
  - preferred_term: Hypomagnesemia
    term:
      id: HP:0002917
      label: Hypomagnesemia
  evidence:
  - reference: PMID:28003083
    reference_title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "oral magnesium and potassium supplements"
    explanation: KDIGO consensus supports magnesium supplementation.
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment mainly consisted of potassium (94%) and magnesium (50%) supplementation."
    explanation: Large survey documents magnesium supplementation in current clinical practice.
- name: Potassium-sparing medication
  description: >
    Potassium-sparing agents such as amiloride, spironolactone, or eplerenone
    can be used when supplementation alone does not adequately improve serum
    potassium or symptoms.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amiloride
      term:
        id: CHEBI:2639
        label: amiloride
    - preferred_term: spironolactone
      term:
        id: CHEBI:9241
        label: spironolactone
    - preferred_term: eplerenone
      term:
        id: CHEBI:31547
        label: eplerenone
  target_phenotypes:
  - preferred_term: Hypokalemia
    term:
      id: HP:0002900
      label: Hypokalemia
  evidence:
  - reference: PMID:41278357
    reference_title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Potassium-sparing medication (used in 33%) slightly increased blood potassium levels (3.2 vs. 3.1 mmol/l)."
    explanation: Large survey supports use and modest biochemical effect of potassium-sparing medication.
notes: >
  This curation uses ORPHA:358 as the direct disease mapping. The mechanism is
  centered on SLC12A3/NCC loss in the distal convoluted tubule, renal salt
  wasting with extracellular volume contraction, secondary RAAS activation,
  collecting-duct potassium and hydrogen ion loss, hypokalemic metabolic
  alkalosis, and incompletely resolved distal calcium and magnesium handling
  that produces hypomagnesemia and hypocalciuria. CLCNKB is recorded because
  Orphanet lists it for ORPHA:358, but the central molecular mechanism is
  SLC12A3-associated Gitelman syndrome rather than classic Bartter syndrome
  type 3.
references:
- reference: ORPHA:358
  title: Gitelman syndrome
  findings: []
- reference: PMID:8528245
  title: "Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter."
  findings: []
- reference: PMID:28744758
  title: "Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities."
  findings: []
- reference: PMID:28003083
  title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference."
  findings:
  - statement: '2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046.'
    supporting_text: '2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046.'
    evidence:
    - reference: PMID:28003083
      reference_title: 'Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046.'
      explanation: Deep research cited this publication as relevant literature for Gitelman Syndrome.
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
- reference: PMID:35173827
  title: Renal calcium and magnesium handling in Gitelman syndrome.
  findings: []
- reference: PMID:20848653
  title: Generation and analysis of the thiazide-sensitive Na+ -Cl- cotransporter (Ncc/Slc12a3) Ser707X knockin mouse as a model of Gitelman syndrome.
  findings: []
- reference: PMID:17329572
  title: "Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome."
  findings: []
- reference: PMID:20650971
  title: "Gitelman syndrome: pathophysiological and clinical aspects."
  findings: []
- reference: PMID:30867665
  title: "Gitelman Syndrome: A Rare Cause of Seizure Disorder and a Systematic Review."
  findings: []
- reference: PMID:41278357
  title: "Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome."
  findings: []
- reference: DOI:10.1016/j.ekir.2018.09.015
  title: Clinical and Genetic Characteristics in Patients With Gitelman Syndrome
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings:
  - statement: Clinical and Genetic Characteristics in Patients With Gitelman Syndrome
    supporting_text: Clinical and Genetic Characteristics in Patients With Gitelman Syndrome
- reference: DOI:10.1093/ndt/gfw019
  title: 'Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes'
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings:
  - statement: Gitelman syndrome (GS) is a rare recessively inherited renal tubulopathy associated with renal potassium (K) and magnesium (Mg) loss.
    supporting_text: Gitelman syndrome (GS) is a rare recessively inherited renal tubulopathy associated with renal potassium (K) and magnesium (Mg) loss.
    evidence:
    - reference: DOI:10.1093/ndt/gfw019
      reference_title: 'Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Gitelman syndrome (GS) is a rare recessively inherited renal tubulopathy associated with renal potassium (K) and magnesium (Mg) loss.
      explanation: Deep research cited this publication as relevant literature for Gitelman Syndrome.
- reference: DOI:10.1101/2025.04.28.25326317
  title: Mutations in 329 probands with suspected renal electrolyte disorders
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings:
  - statement: The spectrum of coding and non-coding of mutations that contribute to Mendelian diseases is largely unknown.
    supporting_text: The spectrum of coding and non-coding of mutations that contribute to Mendelian diseases is largely unknown.
    evidence:
    - reference: DOI:10.1101/2025.04.28.25326317
      reference_title: Mutations in 329 probands with suspected renal electrolyte disorders
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The spectrum of coding and non-coding of mutations that contribute to Mendelian diseases is largely unknown.
      explanation: Deep research cited this publication as relevant literature for Gitelman Syndrome.
- reference: DOI:10.1681/asn.2022050627
  title: Long-Read Sequencing Identifies Novel Pathogenic Intronic Variants in Gitelman Syndrome
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings:
  - statement: Significance Statement Gitelman syndrome is caused by biallelic pathogenic variants in SLC12A3 , which encodes the thiazide-sensitive sodium-chloride cotransporter (NCC).
    supporting_text: Significance Statement Gitelman syndrome is caused by biallelic pathogenic variants in SLC12A3 , which encodes the thiazide-sensitive sodium-chloride cotransporter (NCC).
    evidence:
    - reference: DOI:10.1681/asn.2022050627
      reference_title: Long-Read Sequencing Identifies Novel Pathogenic Intronic Variants in Gitelman Syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Significance Statement Gitelman syndrome is caused by biallelic pathogenic variants in SLC12A3 , which encodes the thiazide-sensitive sodium-chloride cotransporter (NCC).
      explanation: Deep research cited this publication as relevant literature for Gitelman Syndrome.
- reference: DOI:10.3389/fped.2023.1188098
  title: 'Sudden cardiac arrest in a child with Gitelman syndrome: a case report and literature review'
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings:
  - statement: Salt-losing tubulopathies are well-recognised diseases predisposing to metabolic disturbances in affected patients.
    supporting_text: Salt-losing tubulopathies are well-recognised diseases predisposing to metabolic disturbances in affected patients.
    evidence:
    - reference: DOI:10.3389/fped.2023.1188098
      reference_title: 'Sudden cardiac arrest in a child with Gitelman syndrome: a case report and literature review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Salt-losing tubulopathies are well-recognised diseases predisposing to metabolic disturbances in affected patients.
      explanation: Deep research cited this publication as relevant literature for Gitelman Syndrome.
- reference: DOI:10.3390/ijms24033019
  title: CRISPR-Cas9-Mediated Correction of SLC12A3 Gene Mutation Rescues the Gitelman’s Disease Phenotype in a Patient-Derived Kidney Organoid System
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings:
  - statement: CRISPR-Cas9-Mediated Correction of SLC12A3 Gene Mutation Rescues the Gitelman’s Disease Phenotype in a Patient-Derived Kidney Organoid System
    supporting_text: The aim of this study is to explore the possibility of modeling Gitelman’s disease (GIT) with human-induced pluripotent stem cell (hiPSC)-derived kidney organoids and to test whether gene correction using CRISPR/Cas9 can rescue the disease phenotype of GIT.
    evidence:
    - reference: DOI:10.3390/ijms24033019
      reference_title: CRISPR-Cas9-Mediated Correction of SLC12A3 Gene Mutation Rescues the Gitelman’s Disease Phenotype in a Patient-Derived Kidney Organoid System
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The aim of this study is to explore the possibility of modeling Gitelman’s disease (GIT) with human-induced pluripotent stem cell (hiPSC)-derived kidney organoids and to test whether gene correction using CRISPR/Cas9 can rescue the disease phenotype of GIT.
      explanation: Deep research cited this publication as relevant literature for Gitelman Syndrome.
- reference: DOI:10.3390/ijms25179332
  title: Untangling the Uncertain Role of Overactivation of the Renin–Angiotensin–Aldosterone System with the Aging Process Based on Sodium Wasting Human Models
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings:
  - statement: Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
    supporting_text: Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
    evidence:
    - reference: DOI:10.3390/ijms25179332
      reference_title: Untangling the Uncertain Role of Overactivation of the Renin–Angiotensin–Aldosterone System with the Aging Process Based on Sodium Wasting Human Models
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
      explanation: Deep research cited this publication as relevant literature for Gitelman Syndrome.
- reference: DOI:10.1016/j.kint.2016.09.046
  title: "Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference"
  found_in:
  - Gitelman_Syndrome-deep-research-falcon.md
  findings: []
📚

References & Deep Research

References

18
ORPHA:358
Gitelman syndrome
No top-level findings curated for this source.
PMID:8528245
Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter.
No top-level findings curated for this source.
PMID:28744758
Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities.
No top-level findings curated for this source.
PMID:28003083
Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
1 finding
2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046.
"2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046."
Show evidence (1 reference)
PMID:28003083 SUPPORT Other
"2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046."
Deep research cited this publication as relevant literature for Gitelman Syndrome.
PMID:35173827
Renal calcium and magnesium handling in Gitelman syndrome.
No top-level findings curated for this source.
PMID:20848653
Generation and analysis of the thiazide-sensitive Na+ -Cl- cotransporter (Ncc/Slc12a3) Ser707X knockin mouse as a model of Gitelman syndrome.
No top-level findings curated for this source.
PMID:17329572
Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome.
No top-level findings curated for this source.
PMID:20650971
Gitelman syndrome: pathophysiological and clinical aspects.
No top-level findings curated for this source.
PMID:30867665
Gitelman Syndrome: A Rare Cause of Seizure Disorder and a Systematic Review.
No top-level findings curated for this source.
PMID:41278357
Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome.
No top-level findings curated for this source.
DOI:10.1016/j.ekir.2018.09.015
Clinical and Genetic Characteristics in Patients With Gitelman Syndrome
1 finding
Clinical and Genetic Characteristics in Patients With Gitelman Syndrome
"Clinical and Genetic Characteristics in Patients With Gitelman Syndrome"
DOI:10.1093/ndt/gfw019
Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes
1 finding
Gitelman syndrome (GS) is a rare recessively inherited renal tubulopathy associated with renal potassium (K) and magnesium (Mg) loss.
"Gitelman syndrome (GS) is a rare recessively inherited renal tubulopathy associated with renal potassium (K) and magnesium (Mg) loss."
Show evidence (1 reference)
DOI:10.1093/ndt/gfw019 SUPPORT Human Clinical
"Gitelman syndrome (GS) is a rare recessively inherited renal tubulopathy associated with renal potassium (K) and magnesium (Mg) loss."
Deep research cited this publication as relevant literature for Gitelman Syndrome.
DOI:10.1101/2025.04.28.25326317
Mutations in 329 probands with suspected renal electrolyte disorders
1 finding
The spectrum of coding and non-coding of mutations that contribute to Mendelian diseases is largely unknown.
"The spectrum of coding and non-coding of mutations that contribute to Mendelian diseases is largely unknown."
Show evidence (1 reference)
DOI:10.1101/2025.04.28.25326317 SUPPORT Human Clinical
"The spectrum of coding and non-coding of mutations that contribute to Mendelian diseases is largely unknown."
Deep research cited this publication as relevant literature for Gitelman Syndrome.
DOI:10.1681/asn.2022050627
Long-Read Sequencing Identifies Novel Pathogenic Intronic Variants in Gitelman Syndrome
1 finding
Significance Statement Gitelman syndrome is caused by biallelic pathogenic variants in SLC12A3 , which encodes the thiazide-sensitive sodium-chloride cotransporter (NCC).
"Significance Statement Gitelman syndrome is caused by biallelic pathogenic variants in SLC12A3 , which encodes the thiazide-sensitive sodium-chloride cotransporter (NCC)."
Show evidence (1 reference)
DOI:10.1681/asn.2022050627 SUPPORT Other
"Significance Statement Gitelman syndrome is caused by biallelic pathogenic variants in SLC12A3 , which encodes the thiazide-sensitive sodium-chloride cotransporter (NCC)."
Deep research cited this publication as relevant literature for Gitelman Syndrome.
DOI:10.3389/fped.2023.1188098
Sudden cardiac arrest in a child with Gitelman syndrome: a case report and literature review
1 finding
Salt-losing tubulopathies are well-recognised diseases predisposing to metabolic disturbances in affected patients.
"Salt-losing tubulopathies are well-recognised diseases predisposing to metabolic disturbances in affected patients."
Show evidence (1 reference)
DOI:10.3389/fped.2023.1188098 SUPPORT Human Clinical
"Salt-losing tubulopathies are well-recognised diseases predisposing to metabolic disturbances in affected patients."
Deep research cited this publication as relevant literature for Gitelman Syndrome.
DOI:10.3390/ijms24033019
CRISPR-Cas9-Mediated Correction of SLC12A3 Gene Mutation Rescues the Gitelman’s Disease Phenotype in a Patient-Derived Kidney Organoid System
1 finding
CRISPR-Cas9-Mediated Correction of SLC12A3 Gene Mutation Rescues the Gitelman’s Disease Phenotype in a Patient-Derived Kidney Organoid System
"The aim of this study is to explore the possibility of modeling Gitelman’s disease (GIT) with human-induced pluripotent stem cell (hiPSC)-derived kidney organoids and to test whether gene correction using CRISPR/Cas9 can rescue the disease phenotype of GIT."
Show evidence (1 reference)
DOI:10.3390/ijms24033019 SUPPORT Human Clinical
"The aim of this study is to explore the possibility of modeling Gitelman’s disease (GIT) with human-induced pluripotent stem cell (hiPSC)-derived kidney organoids and to test whether gene correction using CRISPR/Cas9 can rescue the disease phenotype of GIT."
Deep research cited this publication as relevant literature for Gitelman Syndrome.
DOI:10.3390/ijms25179332
Untangling the Uncertain Role of Overactivation of the Renin–Angiotensin–Aldosterone System with the Aging Process Based on Sodium Wasting Human Models
1 finding
Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
"Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases."
Show evidence (1 reference)
DOI:10.3390/ijms25179332 SUPPORT Human Clinical
"Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases."
Deep research cited this publication as relevant literature for Gitelman Syndrome.
DOI:10.1016/j.kint.2016.09.046
Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 20 citations 2026-05-08T19:11:49.918148

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Gitelman syndrome
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Gitelman syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive disease characteristics report: Gitelman syndrome (Mendelian tubulopathy)

Executive summary (current understanding)

Gitelman syndrome (GS) is a rare, recessively inherited salt-losing tubulopathy characterized by hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria, caused by biallelic inactivating variants in SLC12A3, which encodes the thiazide-sensitive sodium–chloride cotransporter (NCC/NCCT) expressed in the distal convoluted tubule (DCT) (blanchard2017gitelmansyndromeconsensus pages 1-2, fujimura2019clinicalandgenetic pages 1-2, thimm2024untanglingtheuncertain pages 1-2). GS is clinically important because chronic potassium and magnesium depletion can substantially reduce quality of life and can precipitate cardiac arrhythmias, including rare life-threatening events (blanchard2017gitelmansyndromeconsensus pages 4-5, zieg2023suddencardiacarrest pages 1-2).

A compact evidence-backed summary table is provided below.

Topic Summary Source (year; journal) DOI/URL Evidence type
Disease name / synonyms Gitelman syndrome (GS); also referred to as familial hypokalemia-hypomagnesemia in KDIGO and review literature (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2) Blanchard et al. 2017; Kidney International (blanchard2017gitelmansyndromeconsensus pages 1-2) https://doi.org/10.1016/j.kint.2016.09.046 Guideline / consensus
Inheritance Autosomal recessive / recessively inherited salt-losing tubulopathy caused by biallelic inactivating variants (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2) Blanchard et al. 2017; Kidney International (blanchard2017gitelmansyndromeconsensus pages 1-2) https://doi.org/10.1016/j.kint.2016.09.046 Guideline / consensus
Causal gene / protein SLC12A3 encodes the thiazide-sensitive sodium-chloride cotransporter (NCC/NCCT) in the apical membrane of distal convoluted tubule cells; loss of function causes GS (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2, fujimura2019clinicalandgenetic pages 1-2) Blanchard et al. 2017; Kidney International (blanchard2017gitelmansyndromeconsensus pages 1-2) https://doi.org/10.1016/j.kint.2016.09.046 Guideline / consensus
Key biochemical hallmarks Core biochemical pattern: chronic hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalciuria, often with hyperreninemic hyperaldosteronism and normotension; KDIGO notes hypocalciuria and hypomagnesemia are highly predictive though variable (blanchard2017gitelmansyndromeconsensus pages 1-2, blanchard2017gitelmansyndromeconsensus pages 4-5, zieg2023suddencardiacarrest pages 1-2) Blanchard et al. 2017; Kidney International (blanchard2017gitelmansyndromeconsensus pages 1-2) https://doi.org/10.1016/j.kint.2016.09.046 Guideline / consensus
Prevalence estimate (general / mainly European ancestry) KDIGO review: prevalence ~1 to 10 per 40,000; described as arguably the most frequent inherited tubulopathy (blanchard2017gitelmansyndromeconsensus pages 1-2) Blanchard et al. 2017; Kidney International (blanchard2017gitelmansyndromeconsensus pages 1-2) https://doi.org/10.1016/j.kint.2016.09.046 Guideline / consensus
Prevalence estimate (case report literature) Pediatric case report/literature review cites prevalence ~25 per million (zieg2023suddencardiacarrest pages 1-2) Zieg et al. 2023; Frontiers in Pediatrics (zieg2023suddencardiacarrest pages 1-2) https://doi.org/10.3389/fped.2023.1188098 Case report / literature review
Prevalence estimate (Caucasian / Asian populations) 2024 review states estimated prevalence 1:40,000 in Caucasian individuals and ~1.7 per 1000 in an Asian population; review also gives OMIM 263800 (thimm2024untanglingtheuncertain pages 1-2) Thimm & Adjaye 2024; International Journal of Molecular Sciences (thimm2024untanglingtheuncertain pages 1-2) https://doi.org/10.3390/ijms25179332 Review
Genetic spectrum KDIGO: >350 SLC12A3 mutations reported; many patients are compound heterozygotes; some clinically diagnosed patients carry only one detected pathogenic variant on routine testing (blanchard2017gitelmansyndromeconsensus pages 1-2). Japanese cohort notes ~500 different mutations reported, including nonsense, splice-site, and missense (fujimura2019clinicalandgenetic pages 1-2) Fujimura et al. 2019; Kidney International Reports (fujimura2019clinicalandgenetic pages 1-2) https://doi.org/10.1016/j.ekir.2018.09.015 Cohort
Cohort clinical anchors In 185 genetically proven Japanese cases, diagnosis followed chance blood tests (54.7%), tetany (32.6%), short stature (7.2%); median serum K 2.5 mEq/L and serum Mg 1.6 mg/dL (fujimura2019clinicalandgenetic pages 1-2) Fujimura et al. 2019; Kidney International Reports (fujimura2019clinicalandgenetic pages 1-2) https://doi.org/10.1016/j.ekir.2018.09.015 Cohort
Real-world diagnostic genetics update Long-read sequencing study found a second likely pathogenic/pathogenic variant in 45/67 (67%) patients with previously monoallelic/unsolved GS; 16/45 resolved cases involved intronic variants outside canonical splice sites, supporting second-tier long-read testing (blanchard2017gitelmansyndromeconsensus pages 4-5) Viering et al. 2023; Journal of the American Society of Nephrology (blanchard2017gitelmansyndromeconsensus pages 4-5) https://doi.org/10.1681/ASN.2022050627 Cohort / diagnostic study
Key guideline / consensus source KDIGO Controversies Conference consensus recommends diagnosis based on biochemical phenotype plus genetic testing; management with liberal salt intake and oral magnesium and potassium supplementation; gene panels should include SLC12A3, CLCNKB, HNF1B at minimum (blanchard2017gitelmansyndromeconsensus pages 4-5, blanchard2017gitelmansyndromeconsensus pages 1-2) Blanchard et al. 2017; Kidney International (blanchard2017gitelmansyndromeconsensus pages 4-5) https://doi.org/10.1016/j.kint.2016.09.046 Guideline / consensus
Additional management source Modified-release magnesium lactate cohort: 89% preferred the regimen, 68% reported improved symptom burden, and biochemistry improved in 91% of continuing patients switched from other preparations (robinson2017magnesiumlactatein pages 2-3) Robinson & Karet Frankl 2017; Nephrology Dialysis Transplantation (robinson2017magnesiumlactatein pages 2-3) https://doi.org/10.1093/ndt/gfw019 Cohort / patient-reported outcomes

Table: This table compacts the most actionable disease-level facts for Gitelman syndrome: name/synonyms, inheritance, causal gene and transporter, hallmark biochemistry, prevalence estimates across populations, and the main consensus/guideline and cohort sources supporting diagnosis and management.

1. Disease information

1.1 What is the disease?

Definition/overview. KDIGO consensus defines GS as “a rare, salt-losing tubulopathy characterized by hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria” and caused by inactivating SLC12A3 variants encoding NCC (blanchard2017gitelmansyndromeconsensus pages 1-2).

Typical clinical context. GS is often detected in adolescence/adulthood, sometimes incidentally or with nonspecific neuromuscular symptoms (fatigue, weakness, cramps), but severe manifestations can occur (blanchard2017gitelmansyndromeconsensus pages 1-2, fujimura2019clinicalandgenetic pages 1-2).

1.2 Key identifiers

  • OMIM: 263800 (explicitly stated in a 2024 review) (thimm2024untanglingtheuncertain pages 1-2).
  • MONDO / Orphanet (Orpha code) / ICD-10/ICD-11 / MeSH: Not extractable from the retrieved full-text evidence in this run; therefore, no evidence-backed identifiers can be asserted here.

1.3 Synonyms / alternative names

  • “familial hypokalemia–hypomagnesemia” (thimm2024untanglingtheuncertain pages 1-2, blanchard2017gitelmansyndromeconsensus pages 1-2).

1.4 Evidence provenance (patient-level vs aggregated)

Evidence used here includes: an international consensus/guideline document (aggregated expert consensus) (blanchard2017gitelmansyndromeconsensus pages 1-2), a national cohort (aggregated observational clinical data) (fujimura2019clinicalandgenetic pages 1-2), a case report with literature review (patient-level + literature synthesis) (zieg2023suddencardiacarrest pages 1-2), a patient-reported outcomes cohort (robinson2017magnesiumlactatein pages 2-3), and an experimental iPSC-organoid study (in vitro model) (lim2023crisprcas9mediatedcorrectionof pages 2-6).

2. Etiology

2.1 Disease causal factors

Primary cause (genetic/mechanistic). GS is caused by biallelic inactivating pathogenic variants in SLC12A3, leading to loss of function of NCC/NCCT in the DCT (blanchard2017gitelmansyndromeconsensus pages 1-2, fujimura2019clinicalandgenetic pages 1-2, thimm2024untanglingtheuncertain pages 1-2).

Variant spectrum (classes). A 2024 review summarizes that >350 distinct SLC12A3 mutations have been described and provides approximate distribution: missense/nonsense (~62.1%), splice (~13–14%), and small deletions (~12%), with other/large rearrangements comprising the remainder (thimm2024untanglingtheuncertain pages 2-4). A Japanese cohort paper notes ~500 different SLC12A3 mutations have been reported, including nonsense, splice-site, and missense variants (fujimura2019clinicalandgenetic pages 1-2).

2.2 Risk factors

  • Genetic risk: Having biallelic pathogenic variants in SLC12A3 is causal (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2).
  • Non-genetic “mimics” (important diagnostic risk context): KDIGO notes a GS-like phenotype can occur with mutations in other genes (e.g., CLCNKB for classic Bartter type III), which increases misclassification risk without genetic testing (blanchard2017gitelmansyndromeconsensus pages 1-2).

2.3 Protective factors

No evidence-backed protective genetic or environmental factors were identified in the retrieved corpus.

2.4 Gene–environment interactions

No direct gene–environment interaction studies were retrieved in the accessible evidence. Clinically, intercurrent illness and/or medication/exposure patterns can unmask or exacerbate electrolyte derangements, but robust GxE evidence is not established in the cited texts.

3. Phenotypes

3.1 Core phenotype types

Laboratory abnormalities (hallmark). Chronic hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria are core, with renin–aldosterone system activation typical; normotension/low blood pressure is common (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2, zieg2023suddencardiacarrest pages 1-2).

Symptoms/signs. KDIGO lists salt craving; muscle weakness/fatigue; limited endurance; episodes of fainting; cramps/tetany/paresthesia/carpopedal spasms; growth retardation/puberty delay/short stature; thirst/abnormal drinking; abdominal pain, with dizziness/vertigo/polyuria/nocturia/palpitations/joint pain/visual problems sometimes in adults (blanchard2017gitelmansyndromeconsensus pages 1-2).

3.2 Phenotype characteristics (age, severity, frequencies)

Age at onset. GS can present in childhood and occasionally neonatally, but often becomes clinically apparent later; a 2023 pediatric case/literature review states typical onset is after age 6 years but neonatal cases exist (zieg2023suddencardiacarrest pages 1-2). KDIGO likewise notes adolescent/adult presentation is common (blanchard2017gitelmansyndromeconsensus pages 1-2).

Cohort statistics (Japan, n=185 genetically proven). * Diagnostic opportunity: chance blood test 54.7%, tetany 32.6%, short stature 7.2% (fujimura2019clinicalandgenetic pages 1-2). * Complications: short stature 16.3%, febrile convulsion 13.7%, thyroid dysfunction 4.3%, epilepsy 2.5%; QT prolongation detected in one case (fujimura2019clinicalandgenetic pages 1-2). * Biochemical medians (same cohort): serum K 2.5 mEq/L (range 1.2–3.8), serum Mg 1.6 mg/dL (range 0.6–2.7) (fujimura2019clinicalandgenetic pages 1-2).

3.3 Quality-of-life impact

KDIGO consensus explicitly states GS is associated with “a significant reduction in the quality of life” (blanchard2017gitelmansyndromeconsensus pages 1-2). A patient-reported outcomes cohort switching to slow-release magnesium lactate found high preference and symptom improvement (see Treatment section) (robinson2017magnesiumlactatein pages 2-3).

3.4 Suggested HPO terms (non-exhaustive)

Evidence-backed phenotype mapping to HPO is not directly provided in the retrieved papers; the following are suggested mappings based on the cited clinical descriptions: * Hypokalemia (HP:0002900) * Hypomagnesemia (HP:0002917) * Metabolic alkalosis (HP:0001940) * Hypocalciuria (HP:0012073, if available in your HPO version) * Muscle weakness (HP:0001324) * Muscle cramps (HP:0003394) * Tetany (HP:0001285) * Paresthesia (HP:0003401) * Salt craving (HP term may vary; often annotated as abnormal food craving) * Short stature (HP:0004322) * Cardiac arrhythmia (HP:0011675) * Prolonged QT interval (HP:0001657)

4. Genetic / molecular information

4.1 Causal genes

  • SLC12A3 (encodes NCC/NCCT), expressed at the apical membrane of DCT cells (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2).

4.2 Pathogenic variants

Variant types. Missense/nonsense are the largest class; splice variants and small deletions are also substantial contributors (thimm2024untanglingtheuncertain pages 2-4). KDIGO notes larger rearrangements/deletions can occur and may require MLPA for detection (blanchard2017gitelmansyndromeconsensus pages 4-5).

Monoallelic findings and “missing second allele.” KDIGO states that in 15–20% of patients, only one pathogenic mutation is found on routine testing, partly due to noncoding/intronic mutations or other mechanisms (blanchard2017gitelmansyndromeconsensus pages 4-5). A large sequencing cohort preprint reported that WGS in monoallelic cases can detect deep intronic splice-gain variants and small exonic deletions missed by WES, while estimating that truly noncoding pathogenic alleles are a small fraction of all SLC12A3 alleles in that referral cohort (aparicio2025mutationsin329 pages 1-3, aparicio2025mutationsin329 pages 14-16). (Note: this specific cohort is 2025 and preprint status.)

Example pathogenic variants (case-level). A pediatric sudden cardiac arrest case identified two pathogenic SLC12A3 variants: c.2633+1G>A and c.2221G>A (zieg2023suddencardiacarrest pages 1-2).

4.3 Genotype–phenotype correlations / modifiers

In the Japanese cohort (n=185), carriers of common hotspot variants p.Arg642Cys and/or p.Leu858His had significantly higher serum magnesium compared with those without these variants (1.76 vs 1.43 mg/dL; P<0.001), supporting variant-dependent phenotypic modulation (fujimura2019clinicalandgenetic pages 1-2).

Strong evidence for independent modifier genes was not identified in the retrieved evidence beyond case-level comorbidity reports.

4.4 Epigenetic information / chromosomal abnormalities

No GS-specific epigenetic signature or recurrent chromosomal abnormalities were identified in the retrieved evidence. (Epigenetic assays are mainly discussed in differential diagnoses rather than GS itself in available evidence.)

5. Environmental information

No environmental toxin, infectious, or lifestyle causes are established for GS in the retrieved evidence. Environmental/behavioral factors are primarily important as phenocopies (e.g., medication-induced renal wasting) or triggers of symptomatic episodes rather than etiologic causes.

6. Mechanism / pathophysiology

6.1 Causal chain (gene → transporter defect → biochemical phenotype → symptoms)

  1. Biallelic SLC12A3 loss-of-function reduces NCC-mediated NaCl reabsorption in DCT cells (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2).
  2. Reduced NaCl reabsorption causes renal salt wasting, leading to volume contraction and compensatory activation of the renin–angiotensin–aldosterone system (RAAS) (thimm2024untanglingtheuncertain pages 2-4, thimm2024untanglingtheuncertain pages 1-2).
  3. RAAS activation increases distal sodium reabsorption in exchange for potassium and hydrogen secretion, causing hypokalemia and metabolic alkalosis (zieg2023suddencardiacarrest pages 1-2, thimm2024untanglingtheuncertain pages 1-2).
  4. GS features renal magnesium wasting with resultant hypomagnesemia; clinically, hypomagnesemia can worsen hypokalemia and contribute to symptoms (blanchard2017gitelmansyndromeconsensus pages 4-5, thimm2024untanglingtheuncertain pages 1-2).
  5. Low K/Mg can prolong the cardiac action potential and QT interval; KDIGO notes prolonged QT “in ~50% of the patients” and recommends ECG screening, acknowledging rare ventricular tachycardia/sudden death reports (blanchard2017gitelmansyndromeconsensus pages 4-5). A pediatric case report documents ventricular fibrillation/sudden cardiac arrest in GS without a precipitating event (zieg2023suddencardiacarrest pages 1-2).

6.2 Molecular pathways and processes (suggested ontology mappings)

Evidence emphasizes renal electrolyte transport and RAAS physiology (thimm2024untanglingtheuncertain pages 1-2, thimm2024untanglingtheuncertain pages 2-4). Suggested GO terms: * GO:0006811 ion transport * GO:0006814 sodium ion transport * GO:0071436 sodium ion transmembrane transport * GO:0006820 anion transport / chloride transport * GO:0006874 cellular calcium ion homeostasis (downstream DCT effects) * GO:0008202 steroid metabolic process (aldosterone physiology; contextual)

Cell types (suggested CL terms): * Distal convoluted tubule epithelial cell (kidney tubule epithelial cell subtype; CL term depends on ontology version) (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2).

6.3 Immune system involvement

A 2024 review (aging/RAAS framing) states in its abstract that “Individuals with sodium deficiency-associated diseases such as Gitelman syndrome (GS) and Bartter syndrome (BS) show downregulation of inflammation-related processes and have reduced oxidative stress and ROS,” and that GS/BS patients sustain higher SIRT1 activity (thimm2024untanglingtheuncertain pages 1-2). These are mechanistic hypotheses from review-level synthesis rather than GS-specific causal immune pathology.

6.4 Molecular profiling / advanced technologies (latest research)

Patient-derived iPSC kidney organoids + CRISPR correction (2023). A 2023 study generated patient-derived hiPSCs with SLC12A3 mutations and differentiated them into kidney organoids, then used CRISPR/Cas9 to correct the mutation and assess phenotype rescue. Quantitatively, the “number of matured kidney organoids” was lower in patient organoids than control (3.7 ± 0.2/cm² vs 16.7 ± 1.3/cm²), and was partially restored after correction (12.2 ± 0.7/cm² vs 3.7 ± 0.2/cm²) (lim2023crisprcas9mediatedcorrectionof pages 2-6). This provides an in vitro platform for functional validation and potential future therapeutic exploration.

7. Anatomical structures affected

7.1 Primary organs / systems

  • Kidney, especially the distal convoluted tubule (DCT), is the primary affected structure (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2).
  • Secondary system impacts include neuromuscular (cramps, tetany, weakness), cardiac electrophysiology (QT prolongation/arrhythmias), and endocrine/other complications (short stature, thyroid dysfunction) (blanchard2017gitelmansyndromeconsensus pages 1-2, fujimura2019clinicalandgenetic pages 1-2, blanchard2017gitelmansyndromeconsensus pages 4-5).

7.2 Suggested UBERON terms

  • Kidney (UBERON:0002113)
  • Distal convoluted tubule (UBERON:0001285, depending on ontology version)

7.3 Subcellular localization (suggested GO Cellular Component)

NCC/NCCT is localized to the apical membrane of DCT epithelial cells (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2). Suggested GO CC term: GO:0016324 apical plasma membrane.

8. Temporal development

Onset

Typically adolescent/adult detection, but childhood and even neonatal presentation can occur (blanchard2017gitelmansyndromeconsensus pages 1-2, zieg2023suddencardiacarrest pages 1-2).

Progression / course

GS is generally chronic and lifelong, requiring ongoing management. KDIGO highlights high phenotypic variability and potential severity; long-term monitoring is implied by consensus follow-up recommendations, including cardiac monitoring in relevant patients (blanchard2017gitelmansyndromeconsensus pages 1-2, blanchard2017gitelmansyndromeconsensus pages 4-5).

9. Inheritance and population

9.1 Inheritance

Autosomal recessive (biallelic SLC12A3 pathogenic variants) (blanchard2017gitelmansyndromeconsensus pages 1-2, thimm2024untanglingtheuncertain pages 1-2).

9.2 Epidemiology (statistics)

Reported prevalence estimates vary by source/population: * KDIGO (2017): “prevalence at ~1 to 10 per 40,000, and potentially higher in Asia” (blanchard2017gitelmansyndromeconsensus pages 1-2). * Review (2024): “estimated prevalence of 1:40,000 Caucasian individuals” and “estimated at around 1.7 per 1000 people” in an Asian population (thimm2024untanglingtheuncertain pages 1-2). * Pediatric case/literature review (2023): ~“25 per million” (zieg2023suddencardiacarrest pages 1-2).

Carrier frequency and founder effects were not extractable from Orphanet/gnomAD-like sources in this run; therefore they are not asserted.

10. Diagnostics

10.1 Clinical and laboratory evaluation

KDIGO proposes biochemical criteria for suspecting GS (Table 2), which include chronic hypokalemia and associated features. The consensus emphasizes that hypocalciuria plus hypomagnesemia is “highly predictive” though both can be variable (blanchard2017gitelmansyndromeconsensus pages 1-2). A cropped image of this diagnostic criteria table is included as visual evidence (blanchard2017gitelmansyndromeconsensus media 4476f44a).

10.2 Genetic testing (real-world workflows)

KDIGO recommends next-generation sequencing (NGS) diagnostic approaches, noting gene panels should include SLC12A3, CLCNKB, and HNF1B at minimum to address phenotypic overlap and differential diagnosis (blanchard2017gitelmansyndromeconsensus pages 4-5). KDIGO also notes that routine genetic testing can miss noncoding/intronic variants and larger rearrangements, supporting extended analyses (e.g., MLPA) when only one allele is found (blanchard2017gitelmansyndromeconsensus pages 4-5).

10.3 Differential diagnosis (key mimics)

GS-like phenotypes can be caused by CLCNKB variants (classic Bartter syndrome type III) due to overlap at the DCT; other tubulopathies and genetic disorders can mimic GS clinically and biochemically, making molecular testing important for resolution in ambiguous cases (blanchard2017gitelmansyndromeconsensus pages 1-2).

11. Outcome / prognosis

11.1 Survival and mortality

No cohort-derived survival curves or life expectancy estimates were retrieved in accessible evidence.

11.2 Morbidity and complications

  • Cardiac electrophysiology risk. KDIGO states K/Mg depletion can prolong action potential duration and QT interval (noting prolonged QT in ~50% of patients), with isolated reports of ventricular tachycardia and sudden death, motivating ECG surveillance (blanchard2017gitelmansyndromeconsensus pages 4-5).
  • Severe arrhythmia case evidence (2023). A 10-year-old child experienced ventricular fibrillation and sudden cardiac arrest attributed to severe hypokalemia, with subsequent ICD placement and stabilization with electrolyte therapy (zieg2023suddencardiacarrest pages 1-2).
  • Extrarenal complications (cohort). Short stature, febrile convulsions, thyroid dysfunction, epilepsy, and QT prolongation are documented with frequencies in the Japanese cohort (fujimura2019clinicalandgenetic pages 1-2).

12. Treatment

12.1 Standard management (real-world implementation)

KDIGO consensus indicates GS is “usually managed by a liberal salt intake together with oral magnesium and potassium supplements” (blanchard2017gitelmansyndromeconsensus pages 1-2). KDIGO further notes that hypomagnesemia can aggravate and render hypokalemia refractory, supporting combined replacement strategies (blanchard2017gitelmansyndromeconsensus pages 4-5).

Arrhythmia risk management. KDIGO recommends resting ECG, with further cardiology evaluation for symptoms or high-risk features (blanchard2017gitelmansyndromeconsensus pages 4-5).

12.2 Evidence on magnesium formulation: patient-reported outcomes

A specialist-clinic cohort study evaluated slow-release magnesium lactate in genetically proven GS (n=28). Key statistics reported include: * “almost 90% (n=25) choosing to continue long term” (robinson2017magnesiumlactatein pages 2-3). * Side effects vs prior Mg: 59% reported fewer side effects, 32% same, 9% worse (robinson2017magnesiumlactatein pages 2-3). The authors’ abstract further reports preference and symptom/biochemical improvement rates (89% preference; 68% symptom improvement among those preferring; biochemical improvement in 91% of continuing patients switched from other preparations) (robinson2017magnesiumlactatein pages 2-3).

12.3 MAXO (Medical Action Ontology) suggestions (non-exhaustive)

  • Oral potassium supplementation
  • Oral magnesium supplementation
  • Dietary sodium chloride supplementation (liberal salt intake)
  • Electrocardiographic monitoring
  • Genetic testing / gene panel testing

(These are ontology mapping suggestions; MAXO IDs were not provided in the retrieved evidence.)

12.4 Experimental/advanced therapeutics (research stage)

The iPSC kidney organoid + CRISPR correction study demonstrates proof-of-concept gene correction rescuing organoid phenotype metrics, providing “therapeutic insight” at a preclinical stage (lim2023crisprcas9mediatedcorrectionof pages 2-6).

12.5 Clinical trials

ClinicalTrials.gov entries were retrieved by the tool, but the trial text chunks returned were not added to the evidence store with citable context IDs in this run; therefore, trial identifiers and outcomes are not cited here.

13. Prevention

Primary prevention of an autosomal recessive monogenic disorder is not generally feasible outside reproductive genetics.

Genetic counseling and reproductive options. KDIGO notes genetic counseling is recommended and that prenatal/preimplantation testing is technically feasible when two pathogenic variants are identified (blanchard2017gitelmansyndromeconsensus pages 4-5).

Secondary/tertiary prevention. Early identification and electrolyte management aim to prevent complications such as arrhythmias (blanchard2017gitelmansyndromeconsensus pages 4-5, zieg2023suddencardiacarrest pages 1-2).

14. Other species / natural disease

No naturally occurring GS in non-human species was identified in the retrieved evidence.

15. Model organisms and in vitro models

15.1 In vitro patient-derived models (2023 development)

The patient-derived iPSC kidney organoid system with CRISPR correction provides a human-cell-based model for GS, including quantitative phenotypes (organoid maturation counts) that respond to gene correction (lim2023crisprcas9mediatedcorrectionof pages 2-6).

15.2 Suggested model utility

  • Functional validation of candidate SLC12A3 variants
  • Testing strategies to restore NCC expression/function in DCT-like compartments

Evidence excerpt quotes (as requested; from abstracts/full text)

  • KDIGO opening definition: “Gitelman syndrome (GS) is a rare, salt-losing tubulopathy characterized by hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria.” (blanchard2017gitelmansyndromeconsensus pages 1-2)
  • 2024 review abstract statement: “Individuals with sodium deficiency-associated diseases such as Gitelman syndrome (GS) and Bartter syndrome (BS) show downregulation of inflammation-related processes and have reduced oxidative stress and ROS.” (thimm2024untanglingtheuncertain pages 1-2)
  • Magnesium lactate cohort (full text): “patient responses were very positive regarding SRMgL, with almost 90% (n = 25) choosing to continue long term” (robinson2017magnesiumlactatein pages 2-3).

Limitations of this report (evidence availability)

  • Orphanet (Orpha code), ICD-10/ICD-11, MeSH, MONDO IDs were not present in the retrieved full-text evidence; they therefore cannot be asserted with citations here.
  • Cohort-level incidence, mortality, and robust carrier-frequency estimates from population databases were not available in the cited sources.
  • Clinical trial identifiers were retrieved by the tools, but not in a way that produced citable context IDs for this final report.

References

  1. (blanchard2017gitelmansyndromeconsensus pages 1-2): Anne Blanchard, Detlef Bockenhauer, Davide Bolignano, Lorenzo A Calò, Etienne Cosyns, Olivier Devuyst, David H Ellison, Fiona E Karet Frankl, Nine VAM Knoers, Martin Konrad, Shih-Hua Lin, and Rosa Vargas-Poussou. Gitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (kdigo) controversies conference. Kidney international, 91 1:24-33, Feb 2017. URL: https://doi.org/10.1016/j.kint.2016.09.046, doi:10.1016/j.kint.2016.09.046. This article has 443 citations and is from a highest quality peer-reviewed journal.

  2. (fujimura2019clinicalandgenetic pages 1-2): Junya Fujimura, Kandai Nozu, Tomohiko Yamamura, Shogo Minamikawa, Keita Nakanishi, Tomoko Horinouchi, China Nagano, Nana Sakakibara, Koichi Nakanishi, Yuko Shima, Kenichi Miyako, Yoshimi Nozu, Naoya Morisada, Hiroaki Nagase, Takeshi Ninchoji, Hiroshi Kaito, and Kazumoto Iijima. Clinical and genetic characteristics in patients with gitelman syndrome. Kidney International Reports, 4:119-125, Jan 2019. URL: https://doi.org/10.1016/j.ekir.2018.09.015, doi:10.1016/j.ekir.2018.09.015. This article has 98 citations and is from a peer-reviewed journal.

  3. (thimm2024untanglingtheuncertain pages 1-2): Chantelle Thimm and James Adjaye. Untangling the uncertain role of overactivation of the renin–angiotensin–aldosterone system with the aging process based on sodium wasting human models. International Journal of Molecular Sciences, 25:9332, Aug 2024. URL: https://doi.org/10.3390/ijms25179332, doi:10.3390/ijms25179332. This article has 6 citations.

  4. (blanchard2017gitelmansyndromeconsensus pages 4-5): Anne Blanchard, Detlef Bockenhauer, Davide Bolignano, Lorenzo A Calò, Etienne Cosyns, Olivier Devuyst, David H Ellison, Fiona E Karet Frankl, Nine VAM Knoers, Martin Konrad, Shih-Hua Lin, and Rosa Vargas-Poussou. Gitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (kdigo) controversies conference. Kidney international, 91 1:24-33, Feb 2017. URL: https://doi.org/10.1016/j.kint.2016.09.046, doi:10.1016/j.kint.2016.09.046. This article has 443 citations and is from a highest quality peer-reviewed journal.

  5. (zieg2023suddencardiacarrest pages 1-2): Jakub Zieg, Terezia Tavačová, Miroslava Balaščáková, Petra Peldová, Filip Fencl, and Peter Kubuš. Sudden cardiac arrest in a child with gitelman syndrome: a case report and literature review. Frontiers in Pediatrics, Jun 2023. URL: https://doi.org/10.3389/fped.2023.1188098, doi:10.3389/fped.2023.1188098. This article has 2 citations.

  6. (robinson2017magnesiumlactatein pages 2-3): Caroline M. Robinson and Fiona E. Karet Frankl. Magnesium lactate in the treatment of gitelman syndrome: patient-reported outcomes. Nephrology Dialysis Transplantation, 32:508-512, Mar 2017. URL: https://doi.org/10.1093/ndt/gfw019, doi:10.1093/ndt/gfw019. This article has 31 citations and is from a domain leading peer-reviewed journal.

  7. (lim2023crisprcas9mediatedcorrectionof pages 2-6): Sun Woo Lim, Xianying Fang, Sheng Cui, Hanbi Lee, Yoo Jin Shin, Eun Jeong Ko, Kang In Lee, Jae Young Lee, Byung Ha Chung, and Chul Woo Yang. Crispr-cas9-mediated correction of slc12a3 gene mutation rescues the gitelman’s disease phenotype in a patient-derived kidney organoid system. International Journal of Molecular Sciences, 24:3019, Feb 2023. URL: https://doi.org/10.3390/ijms24033019, doi:10.3390/ijms24033019. This article has 12 citations.

  8. (thimm2024untanglingtheuncertain pages 2-4): Chantelle Thimm and James Adjaye. Untangling the uncertain role of overactivation of the renin–angiotensin–aldosterone system with the aging process based on sodium wasting human models. International Journal of Molecular Sciences, 25:9332, Aug 2024. URL: https://doi.org/10.3390/ijms25179332, doi:10.3390/ijms25179332. This article has 6 citations.

  9. (aparicio2025mutationsin329 pages 1-3): Renan Eduardo Aparicio, Sheng Chih Jin, Weilai Dong, Samir Zaidi, Michael C Sierant, James Knight, Robert D Bjornson, Christopher Castaldi, Shrikant M Mane, Thomas M. Kaneko, Carol Nelson-Williams, and Richard P. Lifton. Mutations in 329 probands with suspected renal electrolyte disorders. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.04.28.25326317, doi:10.1101/2025.04.28.25326317. This article has 0 citations.

  10. (aparicio2025mutationsin329 pages 14-16): Renan Eduardo Aparicio, Sheng Chih Jin, Weilai Dong, Samir Zaidi, Michael C Sierant, James Knight, Robert D Bjornson, Christopher Castaldi, Shrikant M Mane, Thomas M. Kaneko, Carol Nelson-Williams, and Richard P. Lifton. Mutations in 329 probands with suspected renal electrolyte disorders. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.04.28.25326317, doi:10.1101/2025.04.28.25326317. This article has 0 citations.

  11. (blanchard2017gitelmansyndromeconsensus media 4476f44a): Anne Blanchard, Detlef Bockenhauer, Davide Bolignano, Lorenzo A Calò, Etienne Cosyns, Olivier Devuyst, David H Ellison, Fiona E Karet Frankl, Nine VAM Knoers, Martin Konrad, Shih-Hua Lin, and Rosa Vargas-Poussou. Gitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (kdigo) controversies conference. Kidney international, 91 1:24-33, Feb 2017. URL: https://doi.org/10.1016/j.kint.2016.09.046, doi:10.1016/j.kint.2016.09.046. This article has 443 citations and is from a highest quality peer-reviewed journal.